Science and Research
MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent or recurrent uveitic macular edema, in eyes with controlled uveitis but persistent macular edema.
Overview
The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent or recurrent uveitic macular edema, in eyes with controlled uveitis but persistent macular edema.
Specifically, it is comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex) for the treatment of persistent /recurrent uveitic macular edema.
- Principal Investigator
Associate Professor Lyndell Lim
The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent or recurrent uveitic macular edema, in eyes with controlled uveitis but persistent macular edema.
Specifically, it is comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex) for the treatment of persistent /recurrent uveitic macular edema.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.